IMSA101 not checked

ImmuneSensor Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Intra-tumoral administration on Days 1 and 15 of every 28-day cycle”In the company’s words, NCT06026254 on ClinicalTrials.gov
Tested for
Solid Tumor, Adult
Main trialPhase 1
“This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).”In the company’s words, NCT06026254 on ClinicalTrials.gov

Other drugs for Solid Tumor, Adult

All 2439 drugs for Solid Tumor, Adult

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Sep 2025 A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
Phase 2Terminated 16 Sep 2024 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2Terminated 20 Nov 2024 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
Phase 1/2Completed 15 Sep 2023 Safety and Efficacy Study of IMSA101 in Refractory Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IMSA101

Following is part of Solo: you see every change to IMSA101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in